COST-EFFECTIVENESS ANALYSIS OF CEMIPLIMAB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA IN SPAIN

被引：0
|
作者：
Sanchez-Marin, J. [1 ]
Leon, L. [2 ]
Sanchez-Hernandez, A. [3 ]
Uria, E. [1 ]
Nieves, D. [1 ]
机构：
[1] Pharmalex, Barcelona, Spain
[2] Complexo Hosp Univ Santiago Compostela SERGAS, Translat Med Oncol Oncomet, Hlth Res Inst Santiago IDIS, Santiago De Compostela, Spain
[3] Consorcio Hosp Prov Castellon, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE327
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [21] Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Konidaris, Gerasimos
    Paul, Eleanor
    Kuznik, Andreas
    Keeping, Sam
    Chen, Chieh-I
    Sasane, Medha
    Xu, Yingxin
    Atsou, Kokuvi
    Ayers, Dieter
    Ruiz, Emily S.
    Khushalani, Nikhil I.
    Cope, Shannon
    VALUE IN HEALTH, 2021, 24 (03) : 377 - 387
  • [22] Cemiplimab in association to chemotherapy in advanced non-small cell lung cancer
    Rousseau, Adrien
    Auclin, Edouard
    BULLETIN DU CANCER, 2023, 110 (10)
  • [23] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB COMPARED TO PEMBROLIZUMAB IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS
    Huang, Y.
    Wang, Y.
    Diaby, K.
    VALUE IN HEALTH, 2022, 25 (07) : S414 - S414
  • [24] COST-EFFECTIVENESS OF TEPOTINIB FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS IN SPAIN
    Arriola, E.
    Batteson, R.
    Hook, E.
    Wheat, H.
    Vioix, H.
    Morros, M.
    Aguila, M.
    de los Santos Real, H.
    Soberon S, Fernandez
    Brines, M.
    Vazquez, S.
    VALUE IN HEALTH, 2023, 26 (06) : S86 - S86
  • [25] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Qiao Liu
    Xia Luo
    Liubao Peng
    Lidan Yi
    Xiaomin Wan
    Xiaohui Zeng
    Chongqing Tan
    Clinical Drug Investigation, 2020, 40 : 129 - 137
  • [26] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Liu, Qiao
    Luo, Xia
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Zeng, Xiaohui
    Tan, Chongqing
    CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
  • [27] Cost-Effectiveness Analysis of Three Diagnostic Strategies for the Detection of EGFR Mutation in Advanced Non-Small Cell Lung Cancer
    Cho, Sun Mi
    Lee, Hye Sun
    Jeon, Soyoung
    Kim, Yoonjung
    Kong, Sun-Young
    Lee, Jin Kyung
    Lee, Kyung-A
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (06) : 605 - 613
  • [28] Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis
    Shaohong Luo
    Xiuhua Weng
    Shen Lin
    Xiaoting Huang
    Lingning Huang
    Wei Zhou
    Xianzhong Guo
    Xiongwei Xu
    International Journal of Clinical Pharmacy, 2022, 44 : 192 - 200
  • [29] Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis
    Luo, Shaohong
    Weng, Xiuhua
    Lin, Shen
    Huang, Xiaoting
    Huang, Lingning
    Zhou, Wei
    Guo, Xianzhong
    Xu, Xiongwei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (01) : 192 - 200
  • [30] Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
    Aziz, Mohamed Ismail Abdul
    Tan, Ling Eng
    Tan, Wan Hui Gloria
    Toh, Chee-Keong
    Loke, Lydia Pui Yee
    Pearce, Fiona
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 952 - 960
12345